
Andrew R Rezvani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10851197/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy, 2022, 28, 109.e1-109.e8.	1.2	12
2	Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults. Nature Communications, 2022, 13, 586.	12.8	21
3	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	1.2	11
4	Impact of conditioning regimen intensity on the outcomes of peripheral Tâ€cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic Tâ€cell lymphoma patients undergoing allogeneic transplant. British Journal of Haematology, 2022, 197, 212-222.	2.5	6
5	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplantation and Cellular Therapy, 2022, 28, 406.e1-406.e6.	1.2	4
6	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 286-291.	1.2	10
7	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	1.4	51
8	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	1.4	119
9	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	5.2	92
10	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood, 2021, 138, 1429-1440.	1.4	54
11	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncology, 2021, 7, 993.	7.1	44
12	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy, 2021, 27, 590.e1-590.e8.	1.2	5
13	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	30.7	273
14	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplantation and Cellular Therapy, 2021, 27, 932.e1-932.e11.	1.2	18
15	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. Transplantation and Cellular Therapy, 2021, 27, 879.e1-879.e3.	1.2	0
16	MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. Blood, 2021, 138, 2955-2955.	1.4	0
17	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. Blood, 2021, 138, 3885-3885.	1.4	2
18	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. Blood, 2021, 138, 741-741.	1.4	4

Andrew R Rezvani

#	Article	IF	CITATIONS
19	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. Blood, 2021, 138, 98-98.	1.4	2
20	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. Blood, 2021, 138, 3956-3956.	1.4	0
21	Costs and Outcomes with Once-Daily versus Every-6-Hour Intravenous Busulfan in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 145-149.	2.0	2
22	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1811-1818.	2.0	4
23	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. Journal of Experimental Medicine, 2020, 217, .	8.5	26
24	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. Blood, 2020, 136, 22-23.	1.4	2
25	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Blood, 2020, 136, 28-29.	1.4	3
26	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. Blood, 2020, 136, 47-48.	1.4	4
27	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. Blood, 2020, 136, 33-34.	1.4	Ο
28	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. Blood, 2020, 136, 48-49.	1.4	0
29	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	1.4	Ο
30	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	1.4	0
31	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. Blood, 2020, 136, 32-33.	1.4	4
32	Incidence of Active Tuberculosis After Hematopoietic Cell Transplantation: A Small but Real Threat. Clinical Infectious Diseases, 2019, 70, 1261-1262.	5.8	2
33	Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study. Blood Advances, 2019, 3, 3602-3612.	5.2	24
34	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 2019, 4, .	5.0	46
35	No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. Blood, 2019, 134, 146-146.	1.4	2
36	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	1.4	4

Andrew R Rezvani

#	Article	IF	CITATIONS
37	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	5.2	27
38	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Journal of Hematology and Oncology, 2017, 10, 117.	17.0	20
39	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
40	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 2017, 1, 1347-1357.	5.2	8
41	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 2016, 128, 2899-2908.	1.4	70
42	Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 4615-4615.	1.4	1
43	Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma Journal of Clinical Oncology, 2016, 34, 8026-8026.	1.6	3
44	Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation Journal of Clinical Oncology, 2016, 34, 7046-7046.	1.6	0
45	Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. Blood, 2016, 128. 4669-4669.	1.4	0
46	Longâ€ŧerm sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 2015, 121, 3709-3716.	4.1	27
47	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
48	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 105-112.	2.0	47
49	Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. Blood, 2015, 126, 1536-1536.	1.4	3
50	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. Blood, 2015, 126, 3232-3232.	1.4	1
51	Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. Blood, 2015, 126, 4340-4340.	1.4	0
52	Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma. Current Opinion in Hematology, 2013, 20, 509-514.	2.5	7
53	Nonâ€myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large Bâ€cell lymphoma: a multicentre experience. British Journal of Haematology, 2008, 143, 395-403.	2.5	97
54	Separation of graft-vstumor effects from graft-vshost disease in allogeneic hematopoietic cell transplantation. Journal of Autoimmunity, 2008, 30, 172-179.	6.5	58

#	Article	IF	CITATIONS
55	Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opinion on Biological Therapy, 2008, 8, 161-179.	3.1	17
56	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 211-217.	1.6	186